Caffeine and Cerebrovascular Reactivity

NCT ID: NCT04730193

Last Updated: 2022-08-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-01
• Study Completion Date: 2022-08-01

Brief Summary

Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vascula-ture. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow a more efficient dynamic blood flow regulation through neurovascular coupling. This study will use standardized dose of caffeine to test its effect on NVC responses in cerebral and retinal arterioles.

Detailed Description

Normal brain function is critically dependent on moment-to-moment adjustment of cerebral blood flow to match demands of activated neurons. This process is known as neurovascular coupling (NVC) and recent in vivo studies demonstrate that impairment of NVC responses is associated with worse cognitive performance. Several methods are available to measure NVC responses in human subjects, including transcranial Doppler (TCD), functional near infrared spectroscopy (fNIRS), and dynamic retinal vessel analysis (DVA). Although all these methodologies aim to measure hemodynamic changes in the brain vasculature in response to cognitive, motor, or visual stimulation, the responses are evaluated on the different levels of cerebral vasculature including microvasculature (fNIRS), large cerebral vessels such as middle cerebral artery (TCD), or in the arterioles and venules of the retina (DVA). Currently, there are limited data available on the simultaneous assessment of NVC responses using these methodologies.

Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vasculature. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow a more efficient dynamic blood flow regulation through neurovascular coupling. This study will use standardized dose of caffeine to test its effect on NVC responses in cerebral and retinal arterioles.

This study is designed to establish the direct link between reactivity in the cerebral and retinal micro- and macrovasculature. To achieve this goal, a prospective, single-blinded, placebo controlled, cross-over study will be employed to evaluate changes in the NVC responses measured simultaneously with DVA and TCD, or DVA and fNIRS before and after administration of 100mg of incapsulated caffeine or placebo pill.

Conditions

Caffeine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: TRIPLE

Study Groups

Control

Participants randomized to placebo group will receive placebo capsule

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo pill will be formulated with a non active ingredient such as rice flour powder

Caffeine

Participants randomized to caffeine group will receive 100mg caffeine capsule

Group Type: EXPERIMENTAL

Caffeine

Intervention Type: DRUG

Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient

Interventions

Caffeine

Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient

Intervention Type: DRUG

Placebo

Placebo pill will be formulated with a non active ingredient such as rice flour powder

Intervention Type: DRUG

Other Intervention Names

Trimethylxanthine

Eligibility Criteria

Inclusion Criteria

• English speaking
• Ability to read and write in English
• Competence to provide informed consent
• Non-occludable angle and with no optic neuropathy
• Subjects will be asked to refrain from caffeine consumption for at least 8 hours before participating in the study

Exclusion Criteria

• The history of photosensitive epilepsy
• Intraocular pressure 21 Hgmm or higher
• Eyes with a visual acuity 20/30 or lower or the inability to fixate on fixation markers
• Previous symptoms of glaucoma attack (severe ocular pain and redness, decreased vision, colored halos in combination with headache, nausea and vomiting).
• Known allergies to study drugs
• Pregnancy and breast feeding
• Significant cardiac disease (e.g. heart failure), chest pain in the last 6 months
• Stage-2 high blood pressure not controlled by medication (>160/100 mm Hg)
• Uncontrolled diabetes mellitus; History of stroke; Multiple sclerosis; Chronic obstructive pulmonary disease; Active cancer; Abnormal liver function
• Diagnosis of dementia; Anxiety Disorder
• Absent temporal acoustic windows, intracranial stenosis (for TCD-related studies)
• History of arrhythmias
• Prisoners

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Oklahoma

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andriy Yabluchanskiy, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Oklahoma

Locations

Translational GeroScience Laboratory

Oklahoma City, Oklahoma, United States

Countries

United States

Other Identifiers

12731

Identifier Type: -

Identifier Source: org_study_id